Processa Pharmaceuticals Inc (PCSA)

$0.22 -0.03 (-13.39%)
Market Cap 1.16M
Revenue (ttm) 0.00
Net Income (ttm) -11.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,294,000
Avg Vol 2,400,634
Day's Range N/A - N/A
Shares Out 5.27M
Stochastic %K 27%
Beta 1.05
Analysts Sell
Price Target $6.00

Latest News on PCSA

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Apr 15, 2025, 8:00 AM EDT - 5 days ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Mar 18, 2025, 8:30 AM EDT - 4 weeks ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Feb 7, 2025, 8:00 AM EST - 2 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 30, 2025, 5:17 PM EST - 2 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 2 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Oct 2, 2024, 4:05 PM EDT - 7 months ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Sep 3, 2024, 8:00 AM EDT - 8 months ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:20 AM EDT - 11 months ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 19, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Dec 13, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 30, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 29, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 1:40 PM EST - 1 year ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 9, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Nov 1, 2023, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 13, 2023, 1:08 PM EDT - 1 year ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 17, 2023, 8:05 AM EDT - 1 year ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 4:15 PM EDT - 1 year ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Aug 8, 2023, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Next Generation Chemotherapy: Improved Treatment for More Patients

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Feb 10, 2023, 8:00 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

Jan 4, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

Dec 14, 2022, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript

Nov 12, 2022, 8:55 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2022, 4:00 PM EST - 2 years ago

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST

Nov 2, 2022, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST